antiparasiti

Antiparasitic agent-24 (Compound 14a) is an antiparasitic compound with EC50 values of 0.005 μM for L. maj, 0.069 μM for L. don, 0.82 μM for T. brucei, and 4.1 μM for T. cruzi.

Antiparasitic agent-4 (compound 4q) exhibits high antiparasitic activity with an IC50 of 8.51 μM for Leishmania infantum (L. infantum) and an IC50 of 2.20 μM for Trypanosoma cruzi (T. cruzi). It is also cytotoxic against HepG2 cells with a CC50 of 18.97 μM [1].

Antiparasitic agent-6 (compound 5b) demonstrates selective antiparasitic activity against Leishmania infantum (L. infantum) with an IC50 of 3.89 μM and exhibits cytotoxicity against HepG2 cells with a CC50 of 13.64 μM [1].

Antiparasitic agent-2 (compound 8a) exhibits potent antiparasitic activity against Leishmania infantum (L. infantum) and Trypanosoma cruzi (T. cruzi) with IC50s of 7.28 μM and 2.30 μM, respectively, and demonstrates moderate cytotoxicity against HepG2 cells with a CC50 of 26.79 μM [1].

Antiparasitic agent-8 (Compound 9) exhibits potent antiparasitic activity against Hymenolepis nana, with low levels of cytotoxicity [1].

Antiparasitic agent-7 (compound 5d) exhibits specific antiparasitic activity against Leishmania infantum (L. infantum) with an IC50 value of 2.85 μM and demonstrates cytotoxicity against HepG2 cells with a CC50 value of 10.61 μM [1].

Antiparasitic agent-10 (Compound 94) is a potent anti-parasitic agent with significant anti-schistosomal activity, particularly against adult Schistosoma mansoni, making it a promising candidate for Schistosomiasis research as a treatment option [1].

Antiparasitic agent-5 (compound 8h) exhibits potent selectivity against Leishmania infantum (L. infantum) with an IC50 value of 2.50 μM and displays cytotoxic effects on HepG2 cells with a CC50 value of 6.78 μM [1].

Antiparasitic agent-9 (compound 47) is a highly effective and orally administered antiparasitic agent, demonstrating significant efficacy against the human parasite [1].

Antiparasitic Agent-14 is a potent antiparasitic compound with demonstrated cytotoxicity and antiparasitic activity, effectively inhibiting the growth of trypomastigote and amastigote forms [1].

Antiparasitic Agent-17 (compound 5u), an orally active antiparasitic, demonstrates inhibition against both Chloroquine-sensitive (Pf3D7) and Chloroquine-resistant (PfK1) strains, with IC50 values of 0.96 μM and 1.67 μM, respectively [1].

Antiparasitic agent-18 (compound 3a) exhibits potent and selective antiprotozoal activity, effectively inhibiting T. brucei (EC50 = 0.4 µM), T. cruzi (EC50 = 0.21 µM), and L. donovani (EC50 = 0.26 µM) [1].

Antiparasitic Agent-20 (Compound 1p) exhibits broad-spectrum activity as a parasitic inhibitor, demonstrating efficacy against T. brucei and T. cruzi with EC50 values of 0.09 µM and 14.1 µM, respectively [1].

Antiparasitic Agent-19 (Compound 40) is a broad-spectrum antiparasitic with minimal toxicity to Trypanosoma brucei, Leishmania infantum, and Trypanosoma cruzi [1].

Rapanone (2,5-Dihydroxy-3-tridecyl-[1,4]benzoquinone) is a natural benzoquinone that is a potent and selective inhibitor of human synovial PLA2.